Dr Polat Dursun
@PolatDursun
Followers
3K
Following
3K
Statuses
3K
Kadın Hastalıkları ve Doğum, Jinekolojik Onkoloji, Obstetrics&Gynecology, Gynecologic Oncology, https://t.co/1JRKIC3EeO
GeoTwitt: Ankara, Turkey
Joined February 2010
RT @PolatDursun: Turkiyenin en basarili Bilim adamlari listesi yayinlandi ve bende listedeyim. http://t.co/rfRhAdWfc7
0
13
0
RT @IJGConline: #Images Pelvic chondrosarcoma presenting as an adnexal mass treated with pubic bone resection @PolatDursun 📷 https://t.co/…
0
3
0
RT @DrYukselUrun: Patients with suspected stage III-IV EOC should be evaluated by a gynecologic oncologist, with cancer antigen 125, comput…
0
15
0
RT @DrYukselUrun: Rahim Ağzı ve HPV ilişkili Kanserlerin Önlenmesi İçin Aşılama Önerileri @CDCgov @ASCO @myESMO @saglikbakanligi @WHO https…
0
8
0
RT @theNCI: Cancer survivors are growing in number. In the US, nearly half of survivors have lived 10 or more years after diagnosis, while…
0
142
0
RT @Baselrefky: Trachelechromy +uterine transposition!! 24 yrs cervical rhabdomyosarcoma , 1 cm residue after CT…upper margin wide negative…
0
6
0
RT @DrYukselUrun: ENGOT-OV41/ANITA Trial Update: Adding atezolizumab to platinum-based chemo + maintenance niraparib did not improve PFS o…
0
8
0
RT @DrYukselUrun: HPV vaccines save lives! Cervical cancer mortality in US women <25 dropped 62% (2016-2021). Vaccination works! #HPV #…
0
29
0
RT @agz_eriksson: 🇺🇸steep decline in #cervicalcancer deaths among the 1st women who were eligible for #HPVvaccine in the United States “…o…
0
9
0
RT @DrYukselUrun: 🔥HIPEC in Platinum-Sensitive Recurrent Ovarian Cancer A Phase III trial shows adding HIPEC to secondary cytoreductive sur…
0
14
0
RT @headofmelon: LANCE trial lead-in pilot shows the feasibility of a phase III study to evaluate the efficacy of MIS for interval cytoredu…
0
12
0
RT @DrFMartinelli: HIPEC in Platinum-Sensitive Recurrent #ovariancancer: RCT (HORSE; MITO-18) | @JCO_ASCO 167 pts…
0
12
0
RT @DrFMartinelli: Vaginal Estrogen Use in #breastcancer Survivors: A Systematic Review and Meta-Analysis of Recurrence and Mortality Risks…
0
41
0
RT @DrYukselUrun: 🔬 HIPEC Extends Survival in Recurrent Ovarian Cancer The CHIPOR trial shows adding HIPEC to cytoreductive surgery improv…
0
25
0
RT @esragbilir: 🔥HOT off the press🔥HIPEC➕cytoreductive sx after response to platinum-based CTx @ 1st epithelial #OvarianCancer recurrence s…
0
12
0
RT @AndreasObermair: Sometimes surgeons are the second victims of complications. @IJGConline @ESGO_society @SurgicalPerform @SGO_org
0
5
0
RT @DrYukselUrun: Cadonilimab (bispecific antibody targeting PD-1 and CTLA-4) + chemo improves progression-free survival (12.7 vs. 8.1 mont…
0
7
0
RT @DrYukselUrun: Short-course induction chemotherapy followed by chemoradiotherapy shows significant improvement in 5-year progression-fre…
0
26
0
RT @DrYukselUrun: Atezolizumab combined with chemo and maintenance niraparib in late-relapsing recurrent ovarian cancer didn't significantl…
0
16
0
RT @NCCH_MD: Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally a…
0
6
0
RT @CACancerJournal: PARP inhibitor maintenance in homologous recombination-proficient, advanced-stage epithelial #OvarianCancer needs care…
0
15
0